T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients.
about
The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases.Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort s
P2860
T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@en
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@nl
type
label
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@en
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@nl
prefLabel
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@en
T2238C Atrial Natriuretic Pept ...... chemic Heart Disease Patients.
@nl
P2093
P2860
P50
P1476
T2238C Atrial Natriuretic Pept ...... schemic Heart Disease Patients
@en
P2093
Bruno Trimarco
Chiara De Biase
Emanuele Barbato
Leen Delrue
Massimo Volpe
Teresa Strisciuglio
P2860
P2888
P356
10.1007/S12265-017-9774-9
P407
P50
P577
2017-12-05T00:00:00Z